US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? - Sorbonne Université
Journal Articles JAMA neurology Year : 2021

US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

Abstract

No abstract available

Domains

Human health and pathology
Fichier principal
Vignette du fichier
Manuscript_R2_clean.pdf (382.08 Ko) Télécharger le fichier
Fig with arrows.pdf (80.26 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Nicolas VILLAIN  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03668175

Submitted on : Tuesday, November 15, 2022-10:12:24 AM

Last modification on : Wednesday, January 17, 2024-9:52:07 AM

Long-term archiving on : Thursday, February 16, 2023-6:12:27 PM

Download

Dates and versions

hal-03668175 , version 1 (15-11-2022)

Identifiers

Cite

Vincent Planche, Nicolas Villain. US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. JAMA neurology, 2021, 78 (11), pp.1307. ⟨10.1001/jamaneurol.2021.3126⟩. ⟨hal-03668175⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM CNRS ICM SORBONNE-UNIVERSITE SU-MEDECINE
24 View
301 Download

Altmetric

Share

More